ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
IPO Year:
Exchange: NASDAQ
Website: essapharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/26/2023 | $17.00 | Outperform | Oppenheimer |
8/17/2021 | $36.00 → $22.00 | Outperform | Oppenheimer |
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios. "Lauren's cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the sk
Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors. Dr. Kantoff brings invaluable insight and experience to ESSA as a renowned medical oncologist and leader in the clinical development of new prostate cancer treatments. "Phil's breadth and quality of accomplishments are unmatched, and we are honored to welcome him to ESSA's Board of Directors," stated Richard M. Glickman, L.L.D. (Hon), Chairman of ESSA's
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 9, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 9, 2022 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at eight and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Fr
HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on February 25, 2021 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach,
On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations well beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 5, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will present at the JonesHealthcare Seaside Summit on Monday, July 15, 2024 at 11:00 a.m. PT. David R. Parkinson, President and Chief Executive Officer, will host the presentation and will also participate in a panel discussion titled "Innovations and Challenges in Prostate Cancer" at 9:00 a.m. PT. A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York. David. R. Parkinson, President, and Chief Executive Officer and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings. A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. F
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /C
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /P
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 2:30 p.m. ET in Toronto, Canada. David. R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings. A live webcast of the presentation can be accessed in the Investors/Events &
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 masofaniten plus enzalutamide combination dose expansion study ongoing Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer,
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET. David. R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings. A live webcast of the fireside chat can be access
On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations well beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 5, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /C
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /P
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 masofaniten plus enzalutamide combination dose expansion study ongoing Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer,
Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023 Head-to-head Phase 2 dose expansion underway evaluating masofaniten (EPI-7386)/enzalutamide combination versus enzalutamide monotherapy in patients with mCRPC SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financ
Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023 Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing n
Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023 Continue to enroll patients into the fourth cohort of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide); Phase 1 completion expected in 3Q2023 followed by initiation of the randomized Phase 2 part of the study Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 9, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceu
Earnings Call with Management Team Scheduled for Today at 9:00am EST Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022. Operational & Corporate Updates Our Collaboration and License Agreement with Akeso Inc. ("Akeso") for ivonescimab: On December 5, 2022, Summit and Akeso entered into a Collaboration and License Agreement for ivonescimab, Akeso's breakthrough, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blockin
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, Canada, Feb. 7, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated. "Building on
SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA, Dec. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated. "ESSA achieved major milestones in 2022 with the release of Phase 1 monotherapy and combination data for our lead candidate EPI-7386 from three clinical trials in patients with metastatic castration-resistant prostate cancer ("mCRPC
8-K - ESSA Pharma Inc. (0001633932) (Filer)
10-Q - ESSA Pharma Inc. (0001633932) (Filer)
8-K - ESSA Pharma Inc. (0001633932) (Filer)
10-Q - ESSA Pharma Inc. (0001633932) (Filer)
S-8 - ESSA Pharma Inc. (0001633932) (Filer)
8-K - ESSA Pharma Inc. (0001633932) (Filer)
10-Q - ESSA Pharma Inc. (0001633932) (Filer)
8-K - ESSA Pharma Inc. (0001633932) (Filer)
8-K - ESSA Pharma Inc. (0001633932) (Filer)
DEFA14A - ESSA Pharma Inc. (0001633932) (Filer)
Oppenheimer analyst Leland Gershell maintains ESSA Pharma (NASDAQ:EPIX) with a Outperform and maintains $17 price target.
ESSA Pharma (NASDAQ:EPIX) reported its Q1 earnings results on Tuesday, February 13, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings ESSA Pharma beat estimated earnings by 17.65%, reporting an EPS of $-0.14 versus an estimate of $-0.17. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.09 which was followed by a 0.36% increase in the share price the next day. ** Listen to the earnings announcement yourself by clicking here. ** To track all earnings releases for ESSA Pharma visit their earnings calendar here. This article was generated by Benzinga's automated content engine and review
ESSA Pharma (NASDAQ:EPIX) has outperformed the market over the past 5 years by 3.09% on an annualized basis producing an average annual return of 15.65%. Currently, ESSA Pharma has a market capitalization of $297.22 million. Buying $1000 In EPIX: If an investor had bought $1000 of EPIX stock 5 years ago, it would be worth $2,060.30 today based on a price of $6.73 for EPIX at the time of writing. ESSA Pharma's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engin
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Shares of Booz Allen Hamilton Holding Corporation (NYSE:BAH) rose sharply during Friday’s session after the company reported better-than-expected third-quarter financial results, increased its quarterly dividend and raised FY24 guidance. Booz Allen Hamilton posted adjusted earnings of $1.41 per share, beating market estimates of $1.14 per share. The company’s quarterly sales came in at $2.57 billion versus expectations of $2.54 billion, according to data from Benzinga Pro. Booz Allen Hamilton shares jumped 13.2% to $145.90 on Friday. Here are some other big stocks recording gains in today’s session. AppF
Thursday, ESSA Pharma Inc (NASDAQ:EPIX) shares closed 22.6% lower at $6.80. According to data from Benzinga Pro, session volume stands at 447.615K compared to the average volume (100 days) of 132.003K. The company announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium. Masofaniten is a first-in-class N-terminal domain androgen receptor inhibitor that suppresses androgen activity through a novel mechanism of action and is being developed for prostate cancer. In the patients evaluable for efficacy (n=16), rapid, deep, and durable re
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPCPhase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QDAcross all dosing cohorts, 81% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. While the data are still maturing, median time to PSA progression is currently at 16.6 months.SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Jan. 25, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on d
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Tuesday. Here are some big stocks recording gains in today’s pre-market trading session. MorphoSys AG (NASDAQ:MOR) shares jumped 18.8% to $10.21 in pre-market trading. ESSA Pharma Inc. (NASDAQ:EPIX) shares gained 10.6% to $11.00 in pre-market trading after surging 17% on Friday. Digital World Acquisition Corp. (NASDAQ:DWAC) gained 8.3% to $18.76 in pre-market trading. ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) shares climbed 5.7% to $14.24 in pre-market trading. Nomura Holdings, Inc. (NYSE:NMR) gained 5.3% to $5.01 in pre-market trading. Tilray Brands, Inc. (NASDAQ:TLRY) gained 4.8
Oppenheimer analyst Mark Breidenbach reiterates ESSA Pharma (NASDAQ:EPIX) with a Outperform and maintains $17 price target.
ESSA Pharma (NASDAQ:EPIX) reported quarterly losses of $(0.12) per share. This is a 14.29 percent increase over losses of $(0.14) per share from the same period last year.
ESSA Pharma (NASDAQ:EPIX) reported its Q4 earnings results on Tuesday, December 12, 2023 at 07:00 AM. Here's what investors need to know about the announcement. Earnings ESSA Pharma beat estimated earnings by 42.86%, reporting an EPS of $-0.12 versus an estimate of $-0.21. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.02 which was followed by a 0.36% drop in the share price the next day. ** Listen to the earnings announcement yourself by clicking here. ** To track all earnings releases for ESSA Pharma visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed b
Oppenheimer resumed coverage of ESSA Pharma with a rating of Outperform and set a new price target of $17.00
Oppenheimer reiterated coverage of ESSA Pharma with a rating of Outperform and set a new price target of $22.00 from $36.00 previously
Piper Sandler initiated coverage of ESSA Pharma with a rating of Overweight and set a new price target of $50.00
Piper Sandler initiated coverage of ESSA Pharma with a rating of Overweight and set a new price target of $50.00
HC Wainwright reiterated coverage of ESSA Pharma with a rating of Buy and set a new price target of $32.00 from $36.00 previously
HC Wainwright & Co. reiterated coverage of ESSA Pharma with a rating of Buy and set a new price target of $32.00 from $36.00 previously
Bloom Burton resumed coverage of ESSA Pharma with a rating of Buy
Oppenheimer reiterated coverage of ESSA Pharma with a rating of Outperform and set a new price target of $36.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of ESSA Pharma with a rating of Buy and set a new price target of $36.00 from $17.00 previously